Vertex Pharmaceuticals Incorporated today announced data from a retrospective subanalysis of the Phase 2 PROVE 2 study that showed that 100 percent of patients with the IL28B CC genotype who were new to treatment achieved a viral cure with a total of 12 weeks of treatment with INCIVEK™ tablets, pegylated-interferon and ribavirin.
